anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Administer Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension by the oral route only. Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension can be taken with or without food. Shake well before using. Do not mix Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension with other liquids or medicines. Mixing may change how Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension works.

Always use an accurate milliliter measuring device when administering Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension to ensure that the dose is measured and administered accurately. A household teaspoon is not an accurate measuring device and could lead to overdosage [see Warnings and Precautions (5.5)]. The dosing cup is provided with the 3 oz (70 mL) and 4 oz (115 mL) packaged product. The dosing cup fills for 2.5 mL dose and for 5 mL dose. Instruct the patient to fill to the line that the dose has been prescribed. Do not fill over the dose prescribed. Rinse the measuring cup with water after each use. For prescriptions where a measuring device is not provided, a pharmacist can provide an appropriate measuring device and can provide instructions for measuring the correct dose. Do not overfill. Rinse the measuring device with water after each use.

Advise patients not to increase the dose or dosing frequency of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension because serious adverse events such as respiratory depression may occur with overdosage [see Warnings and Precautions (5.2) and Overdosage (10)]. The dosage of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Suspension should not be increased if cough fails to respond; an unresponsive cough should be reevaluated for possible underlying pathology [see Dosage andAdministration (2.3) and Warnings and Precautions (5.4)].
Of the preventable and treatable diseases, both malaria and pneumonia are significant contributors to under-five mortality in Nigeria. To reduce the burden of these diseases, the Integrated Management of Childhood Illness (IMCI) guidelines were developed by the World Health Organisation (WHO) to be used at first point of contact (e.g., primary healthcare centres) with children under the age of five years old. Preliminary literature review suggests that although interventions based on numerous diagnostic approaches have been trialed, burden from malaria and pneumonia remains unacceptably high in Nigeria, suggesting limited effectiveness of existing approaches. Therefore, this study aims to compare the accuracy of different early diagnostic approaches used in the community(for e.g. the WHO Integrated Management of Childhood Illness (IMCI) guidelines versus the gold standard diagnostic tests comprising microscopy in malaria and chest radiography in pneumonia) in children under the age of five years presenting with suspected malaria and pneumonia to primary healthcare centres in Benin City, Edo State of Nigeria.

The research will compare the accuracy of these various diagnostic approaches using measures such as sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve. The research will also assess patient outcomes like complications, hospitalisation and death following a diagnosis of either pneumonia or malaria in all study participants as well as costs associated with malaria and pneumonia.
CK2 is an anti-apoptotic protein found excessively activated in numerous tumours. With this work we show that CK2 inhibition dramatically influences neuroblastoma growth both in vitro and in vivo. In particular, we describe the identification of CK2-TN03, a CK2 inhibitor that has shown in cellular assays greater efficacy than silmitasertib, the only CK2 inhibitor for clinical use, currently designated as an "orphan drug" for the treatment of cholangiocarcinoma and in clinical trials for medulloblastoma. Our CK2-TN03 inhibitor works by suppressing the activity of the survivin protein, which is amplified in all high-ris k neuroblastomas. The functionality of survivin is directly reduced through the inhibition of its activating phosphorylation by CK2, whereas CK2 also regulates it indirectly, reducing its RNA and protein levels, altering the mdm2 /p53 balance through BRD4 /NMYC. As a result, neuroblastoma cells stall in mitosis for a long time before entering apoptosis. Furthermore, it is important to note that CK2-TN03 does not act on cells that are not actively reproducing and significantly reduces tumour growth in mouse xenografts.
This group will be given Left cricopharyngeal muscle botulinum toxin injection, Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once.
Part A2 will evaluate intermittent dosing of ART0380 in combination with gemcitabine in 21-day cycles. Up to 21 participants will participate in this dose escalation arm.
PURPOSE: To improve uniformity in flavor release, temp. stability and masking properties with respect to taste and aroma by using an encapsulated flavor contg. a flavor component, a rosin-containing resin component and a specific hydrophobic coating component. CONSTITUTION: In this production, 10 to 20 pts.wt. of a rosin (or rosin ester)- containing resin is heated to its melting point and maintained at 85 to 90 deg.C while agitating and, thereafter, if necessary, 1 to 5 pts.wt. of an emulsifying agent (e.g. lecithin) and a certain amount of a sweetening agent are added to the resin and they are mixed together. Then, 5 to 25 pts.wt. of a flavor component (e.g. spearmint oil) is added to this mixture and they are agitated while removing heat from the outside to obtain a homogenous mixture. Subsequently, 45 to 95 pts.wt. of a melt of a hydrophobic coating component selected from fat and/or wax is added to the resulting mixture while agitating and they are mixed together to obtain a mixed material and, thereafter, the mixed material is sprayed to coagulate and solidify the material to obtain the objective encapsulated flavor.
PURPOSE:To obtain the titled compound of high purity by extremely simple operation, by hemolyzing erythrocytes, controlling pH to precipitate and remove hemoglobin, adding a metal salt to the formed supernatant liquid and further controlling the pH to precipitate and remove the residual proteins. CONSTITUTION:Water is added to hemolyze erythrocytes and the resultant hemolyzed solution is then treated at <=6.5 pH to denature hemoglobin. The pH of the above-mentioned hemolyzed solution is then adjusted to 7-8 to precipitate hemoglobin. A metal salt is added to the supernatant liquid free of the above-mentioned precipitates and the pH is further adjusted to 6-9 to remove unnecessary proteins contained in the supernatant liquid as precipitates. Thereby the aimed compound of high purity is obtained. A salt of a transition metal, e.g. Cu, Fe or Mn, or amphoteric metal, e.g. Al or Zn, capable of forming chelate bonds to proteins, dissolving in an acidic solution and precipitating as hydroxides under neutral and alkaline condition is used as the above- mentioned metal salt.
PROBLEM TO BE SOLVED: To obtain the subject composition which decomposes plaque efficiently and gives excellent dental caries preventive effect on malocclusion having a high dental caries risk and on children by formulating fine particles of calcium carbonate with dextranase. SOLUTION: The composition for oral cavity is obtained by mixing (A) preferably 0.1-7 wt.% of fine particles of calcium carbonate, which possesses BET specific surface area of 10-50 cm<2> /g and average grain size of 1 μm or less in the primary grain, based on the whole weight of the composition, (B) 1.5-200 units of dextranase and preferably (C) 0.01-0.5 wt.% of an alkyloyl sarcosinate (e.g. lauroyl sarcosinate and the like). This composition can be prepared as toothpastes, liquid dentifrices, mouth washes and troches. It the case of, for example, dentifrices, the composition can be formulated with abrasives (e.g. silica gel, precipitated silica, etc.), viscosity-increasing agents (e.g. glycerol, sorbitol, etc.), surfactants, sweetening agents, antiseptics, pigments and perfumes.
LUMRYZ is taken orally as a single dose at bedtime. Prepare the dose of LUMRYZ prior to bedtime. Prior to ingestion, the dose of LUMRYZ should be suspended in approximately 1/3 cup (approximately 80 mL) of water in the mixing cup provided [see Instructions for Use]. Do not use hot water [see Clinical Pharmacology (12.3)]. After mixing, consume LUMRYZ within 30 minutes.

Take LUMRYZ at least 2 hours after eating [see Clinical Pharmacology (12.3)].

Patients should take LUMRYZ while in bed and lie down immediately after dosing as LUMRYZ may cause them to fall asleep abruptly without first feeling drowsy. Patients will often fall asleep within 5 minutes of taking LUMRYZ, and will usually fall asleep within 15 minutes, though the time it takes any individual patient to fall asleep may vary from night to night. Patients should remain in bed following ingestion of LUMRYZ.
To simulate the experience of tDCS stimulation, current is ramped on and turned off at the beginning and end of the tDCS session. An additional sham option is to have the current ramp up and down only at the beginning of the sham session, and not at the end. This second sham is supported in the literature as an effective blinding technique, which subjects cannot distinguish from active stimulation (Gandiga et al 2006, Brunoni et al 2012) . One of these sham options will be used for data that will be analyzed together, to be determined based on equipment capabilities and preliminary analysis of blinding efficacy in our cross over design. We will assess the efficacy of sham condition by providing participants and the investigator with a questionnaire on the MRI/tDCS session, wherein they will report whether they thought the tDCS session was active or sham. The MRI operator (or other non protocol personnel) will control active/sham conditions.
Suppositories contain 0.3 to 1.6% by weight of dioctyl sodium sulphosuccinate in a base which melts at about body temperature. The term "base" is defined as including ingredients which, although inert in combatting constipation, may have other therapeutic properties. The major base component may be a synthetic or natural wax, e.g. cocoa butter, with or without white beeswax; mono-, di, and tri-glycerides of saturated fatty acids such as Wecobee R, Witepsol, Imhausen and Masses Esterinum suppository bases; and polyethylene glycols.  Other active ingredients may be: zinc oxide, phenyl mercuric nitrate, bismuth salts, boric acid, hexachlorophene, allantoin, ephedrine, phenylephrine, d-panthenol and local anaesthetics such as Larocaine (Trade Mark), benzocaine, amprotropin phosphate, and diperodon.  The suppositories are useful for softening hard f cal masses.
MANUSCRIPT BACKGROUND AND AIM: The diagnosis and clinical care of patients with von Willebrand disease (VWD) has continued to evolve since the characterization of the von Willebrand factor (VWF) gene in 1985. This condition is almost certainly the most common inherited bleeding disorder, and the major symptomatic burden of the disease is experienced by females during their reproductive years. Diagnosis relies on the identification of a personal and family history of excessive mucocutaneous bleeding, and laboratory features consistent with quantitative and/or qualitative abnormalities of VWF. This review focuses on three aspects of VWD management, with current updates and a look into the future.
MANUSCRIPT THEMES: First, we will address the role of genetics in the diagnosis and possible therapies for VWD. With current technologies, VWD genetic diagnosis is usually confined to the confirmation of type 2 subtypes of the disease and type 3 VWD analysis for family planning. While type 3 VWD is a potential candidate for the application of gene therapy, no treatments are currently close to entering the clinic. Second, the peri-procedural management of patients with VWD remains an important element of care. The choice of product, its dose and schedule all require careful consideration depending upon the type and disruptive nature of the planned procedure. Lastly, in addition to gene therapy, several other novel therapeutic interventions are also being developed for bleeding and prophylaxis in VWD. These include a VWF aptamer interfering with VWF clearance and bioengineered forms of VWF.
NEW MATERIAL:The norbornane derivative of formula I (C2... is ethyl, vinyl or ethylidene; the group of formula II is single or double bond; R1 is 3-5C alkylene; R2 and R3 are H or CH3). EXAMPLE:The compound of formula III. USE:A component of a perfumery composition. The fragrance of the compound is based on woody note, however, it varies from floral note to heavy note, and the compound can be compounded to a perfumery composition having woody note, floral note, cypre note, tobacco note, animal note, green note, etc. It can be used as a scent or flavor component of perfume, cosmetics, soap, etc., artifitial essential oil component, component of deodorant or odor-masking agent, a diluent for perfume, etc. PROCESS:The compound of formula I can be prepared by reacting norbornyl-2- aldehyde of formula IV with cycloalkanone of formula V in the presence of an aldol condensation catalyst such as sodium ethylate at 0-200 deg.C, and dehydrating and reducing the reaction product.
Denosumab 60mg subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
Patients will be included after signing informed consent. After inclusion, patients will continue on standard dosing schedule of risankizumab (i.e. subcutaneous injections at weeks 0 and 4, then every 12 weeks (2x 75mg)). During each study visit blood will be taken in order to quantify Ctroughs and/or anti-drug antibodies towards risankizumab. In addition, Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment (IGA) score will be evaluated by a physician. Patients complete the Dermatology Life Quality Index (DLQI) and European quality of life EQ-5D instrument at each visit.
INTRODUCTION: The urinary bladder undergoes morphological and functional changes in patients with symptomatic benign prostatic enlargement (BPE). These detrusor changes reflect chronically increased intravesical pressure as a result of outlet obstruction. This study aims to determine the relationship between the Pre- and Post-op detrusor wall thickness (DWT), international prostate symptom score (IPSS), and duration of lower urinary tract symptoms (LUTS) in patients who had open simple prostatectomy (OSP).
METHOD: This was a prospective study of a cohort of patients who had OSP for symptomatic BPE. The IPSS and symptom duration for each patient were noted. Each patient also had an abdominal ultrasound scan with a measurement of their DWT. Retropubic OSP was done for each patient. The detrusor wall thickness was also measured 12 weeks after the prostatectomy.
RESULTS: Fifty-two patients completed the study; the mean age was 66.37 ± 8.09 years. The median pre-operative IPSS was 28 (IQR = 13.75), and the median duration of symptoms was 24 months (IQR = 37 months). The mean pre-operative DWT was 4.41 ± 1.38mm, while the mean post-operative DWT was 2.16 ± 0.98mm. The preoperative IPSS (p = 0.833) and duration of symptoms (p = 0.375) did not significantly correlate with the pre-operative DWT. There was a significant reduction in the mean DWT (p < 0.001) and IPSS (p < 0.001) following prostatectomy.
CONCLUSION: DWT appears not to be significantly influenced by the severity or duration of LUTS. However, it reduced significantly following OSP with corresponding improvement in urinary symptoms.
Considering the characteristics of cancer patients and the complexity of care, it is essential to include a separate oncology nursing course in the education curriculum to increase the qualifications of nursing students. During undergraduate nursing education, clinical practices for care in oncological diseases are limited. New approaches are needed that will contribute to increasing the effectiveness of the educational processes of nursing students. Escape room game-based educational approaches, which have begun to be used in nursing education in recent years, are presented as an example of this situation. Escape games are defined as a type of student-centered activity designed to improve students' learning and skills in professional development programs. The main purpose of using escape games in nursing education is to create practice environments where students will gain clinical decision-making competence in order to provide safe and qualified patient care services. This research was designed to determine the effect of the escape room game applied to students taking oncology nursing courses on their academic self-efficacy and critical thinking motivation.
Although methylene blue has been used effectively to identify areas of SIM in several studies, its superiority in identifying dysplasia in the setting of Barrett's esophagus has been inconclusive. In all studies to date dysplastic yield was equivalent or better than protocol techniques while requiring fewer biopsies. Variations in study design, staining technique and inexperience in staining interpretation are some of the reasons. Our goal is to build on the techniques that have been shown to be effective, standardize them for the purposes of our study, and to objectively evaluate if MB directed biopsies are useful in screening Barrett's patients for dysplasia. At the time of EGD when length of Barrett's is determined, patients will be stratified into either intermediate (2-4cm) or long segment (\>4cm) Barrett's. Short segment Barrett's esophagus patients will not be considered, as MB techniques have not proved beneficial in dysplasia detection as previously described 7.
PURPOSE: This IFSO survey aims to describe the current trends of metabolic and bariatric surgery (MBS) reporting on the number and types of surgical and endoluminal procedures performed in 2020 and 2021, in the world and within each IFSO chapter.
METHODS: All national societies belonging to IFSO were asked to complete the survey form. The number and types of procedures performed (surgical and endoluminal interventions) from 2020 to 2021 were documented. A special section focused on the impact of COVID-19, the existence of national protocols for MBS, the use of telemedicine, and any mortality related to MBS. A trend analysis of the data, both worldwide and within each IFSO chapter, was also performed for the period between 2018 and 2021.
RESULTS: Fifty-seven of the 74 (77%) IFSO national societies submitted the survey. Twenty-four of the 57 (42.1%) reported data from their national registries. The total number of surgical and endoluminal procedures performed in 2020 was 507,806 and in 2021 was 598,834. Sleeve gastrectomy (SG) remained the most performed bariatric procedure. Thirty national societies (52%) had regional protocols for MBS during COVID-19, 61.4% supported the use of telemedicine, and only 47.3% collected data on mortality after MBS in 2020. These percentages did not significantly change in 2021 (p > 0.05).
CONCLUSIONS: The number of MBS markedly decreased worldwide during 2020. Although there was a positive trend in 2021, it did not reach the values obtained before the COVID-19 pandemic. SG continued to be the most performed operation. Adjustable gastric banding (AGB) continues to decrease worldwide.
This will be a double blind placebo controlled randomized clinical trial at department of rheumatology, Bangabandhu Seikh Mujib Medical University (BSMMU) from January 2023 to December 2023. Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo. Each patient will be allowed take NSAIDs on requirement basis with documentation and follow non pharmacological treatment of OA. At the end of 6 months, again pain and functional status will be measured by WOMAC scale
BACKGROUND: General anesthesia is common, but concerns regarding post-operative complications and mortality remain. No study has described the Danish patient population undergoing general anesthesia on a national level. The aim of this study was to describe the characteristics and outcomes of patients undergoing general anesthesia in Denmark.
METHODS: This study was a registry-based observational cohort study of adult patients (≥18 years) undergoing general anesthesia in Denmark during 2020 and 2021. Data from nationwide registries covering patient characteristics, anesthesia and procedure information, and patient outcomes were combined. Descriptive statistics were used to present findings, both overall and in subgroups based on the American Society of Anesthesiologists (ASA) classification.
RESULTS: We identified 453,133 cases of general anesthesia in 328,951 unique patients. The median age was 57 years (quartiles: 41, 71), and 242,679 (54%) were females. Data on ASA classification were missing for less than 1% of the population, and ASA II was the most prevalent ASA classification (49%). Among cases of general anesthesia, 0.1% experienced a stroke, 0.2% had in-hospital cardiac arrest, and 3.9% had a stay in the intensive care unit within 30 days. Mortality at 30 days and 1 year were 1.8% and 6.3%, respectively, increasing with a higher ASA classification.
CONCLUSION: This study offers the first comprehensive overview of adult patients undergoing general anesthesia in Denmark. Post-anesthesia complications were few and increased with ASA classification.
PURPOSE:A coronary vasodilator containing an eluate which is obtained by extracting flowers of wild chrysanthemum with an aqueous organic solvent, extracting the extracted solution with a specific organic solvent to give an extraction residue, subjecting the extraction residue to specific column chromatography and eluting the resulting substance with water and eluting the eluate with methanol, etc., as an active ingredient. CONSTITUTION:Flowers of wild chrysanthemum are extracted with water and/or an aqueous organic solvent (e.g. ethanol, etc.). The extracted solution is, directly or after removal of an insoluble substance, extracted with at least one organic solvent selected from an ether, petroleum ether, hexane and benzene to give an extraction residue, which is subjected to column chromatography using porous polymer gel, eluted with water, then with methanol or ethanol to give an eluate, which is used as an active ingredient to give a coronary vasodilator. In the case wherein the aqueous organic solvent is used in the extraction process, the solvent is once removed after the removal of the insoluble substance and preferably the residue is dissolved in water and extracted. This drug is effective for remedying angina pectoris, arteriosclerosis, etc.